Dr. Phoebe R. Trubowitz, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 160
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OR license OR MD22617 · WA license WA MD00039272
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
- Providence St Vincent Medical Center Portland, OR
- Legacy Good Samaritan Medical Center Portland, OR
- Legacy Meridian PArk Medical Center Tualatin, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 160
- Services billed
- 662
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 222 | 123 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 55 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 17 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Portland, OR | 255 |
| Tamoxifen Citrate Other prescribers in Portland, OR | 249 |
| Letrozole Other prescribers in Portland, OR | 134 |
| Exemestane | 52 |
| Acyclovir Other prescribers in Portland, OR | 28 |
| Estradiol Other prescribers in Portland, OR | 27 |
| Verzenio (abemaciclib) | 26 |
| Ibrance (palbociclib) | 26 |
| Everolimus | 22 |
| Jakafi (ruxolitinib phosphate) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,000 in research payments for these studies, mostly to the institutions running them.
- The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.